Trial Profile

A proof of concept phase II study of Buparlisib in HER2 positive breast cancer with brain metastasis following HER2 directed monoclonal antibody therapy

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 29 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Buparlisib (Primary)
Indications Advanced breast cancer; Brain metastases
Focus Proof of concept; Therapeutic Use
Acronyms BLUEBELL
Sponsors Novartis

Most Recent Events

13 Jul 2018 Status changed from recruiting to discontinued.
11 Jul 2016 Planned initiation date changed from 1 Jun 2016 to 15 Sep 2016.
26 Feb 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com